RT Journal Article
SR Electronic
T1 The SARS-CoV-2 B.1.351/V2 variant is outgrowing the B.1.1.7/V1 variant in French regions in April 2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.12.21257130
DO 10.1101/2021.05.12.21257130
A1 Roquebert, Bénédicte
A1 Trombert-Paolantoni, Sabine
A1 Haim-Boukobza, Stéphanie
A1 Lecorche, Emmanuel
A1 Verdurme, Laura
A1 Foulongne, Vincent
A1 Sofonea, Mircea T.
A1 Alizon, Samuel
YR 2021
UL http://medrxiv.org/content/early/2021/05/17/2021.05.12.21257130.abstract
AB SARS-CoV-2 variants threaten our ability to control COVID-19 epidemics. We analyzed 36,590 variant-specific RT-PCR tests performed on samples collected between April 12 and May 7, 2021 in France to compare variant spread. Contrarily to January to March 2021, we found that the V2 variant had a significant transmission advantage over V1 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of V2 and the high levels of immunization in these regions.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04738331Funding StatementWe thank the CNRS, the IRD, the ANR and the Occitanie Region (PHYEPI project) for funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by the Institutional Review Board of the CHU of Montpellier.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon manuscript publication.